Oxford Cannabinoid Technologies Holdings plc

("OCT" or the "Company")

Directors' Dealings

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, announces that it has been informed that Clarissa Sowemimo-Coker, the Chief Executive Officer of the Company, and Julie Pomeroy, the Company's Non-Executive Chair, have today purchased ordinary shares of £0.001 ("Ordinary Shares") in the Company.

Clarissa Sowemimo-Coker, Chief Executive Officer of OCT, said:

"Today marks further evidence of the management's support of OCT, following our participation in a successful fundraise in January 2024 where we also welcomed Cantheon Capital LLC as a cornerstone investor of the Company. Both I and OCT's chair, Julie Pomeroy, have increased our personal shareholdings in OCT, demonstrating our commitment to the business and our resolute belief in the Company's future pipeline. I look forward to continuing to work with colleagues to deliver further for our shareholders with the ultimate aim of helping people living with debilitating conditions."

The PDMR forms are set out below.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company take responsibility for this announcement.

Enquiries:

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCT") is the holding company of Oxford Cannabinoid Technologies Ltd and OCT Victoria Pty Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines initially targeting the US$ multi-billion global pain market.

OCT currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently forecast to reach US$1.17bn by 2028.

OCT's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive licence agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCT now has a portfolio of almost five hundred derivatives and intellectual property rights including fourteen patent families and associated research data.

OCT has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCT's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.